{"transactions":[{"id":1824237,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2023-07-25T01:00:35.000Z","date":"2023-07-20","kind":"grant","planned":false,"acquired":true,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents  restricted stock units that vest in full on July 20, 2024, subject to the Reporting Person's continued service with Orchestra BioMed Holdings, Inc. on such vesting date."}],"balance_after":20913,"source":{"system":"sec-edgar","filing":"0001104659-23-083556","document":"tm2321855-11_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923083556/tm2321855-11_4seq1.xml","form_type":"4"}},{"id":1901070,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Right to Receive Earnout Shares","published_at":"2023-05-08T11:47:30.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":55783,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures Synecor, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein."}],"balance_after":55783,"derivative":{"underlying":"Common Stock","underlying_shares":55783},"source":{"system":"sec-edgar","filing":"0001104659-23-056865","document":"tm2314913-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923056865/tm2314913-1_4seq1.xml","form_type":"4"}},{"id":1901069,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Right to Receive Earnout Shares","published_at":"2023-05-08T11:47:30.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":228073,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein."}],"balance_after":228073,"derivative":{"underlying":"Common Stock","underlying_shares":228073},"source":{"system":"sec-edgar","filing":"0001104659-23-056865","document":"tm2314913-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923056865/tm2314913-1_4seq1.xml","form_type":"4"}},{"id":1901068,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Right to Receive Earnout Shares","published_at":"2023-05-08T11:47:30.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":43761,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures II NY, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein."}],"balance_after":43761,"derivative":{"underlying":"Common Stock","underlying_shares":43761},"source":{"system":"sec-edgar","filing":"0001104659-23-056865","document":"tm2314913-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923056865/tm2314913-1_4seq1.xml","form_type":"4"}},{"id":1901067,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Right to Receive Earnout Shares","published_at":"2023-05-08T11:47:30.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":false,"shares":758,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."}],"balance_after":758,"derivative":{"underlying":"Common Stock","underlying_shares":758},"source":{"system":"sec-edgar","filing":"0001104659-23-056865","document":"tm2314913-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923056865/tm2314913-1_4seq1.xml","form_type":"4"}},{"id":1901066,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2023-05-08T11:47:30.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":55783,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures Synecor, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein."}],"balance_after":312406,"source":{"system":"sec-edgar","filing":"0001104659-23-056865","document":"tm2314913-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923056865/tm2314913-1_4seq1.xml","form_type":"4"}},{"id":1901065,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2023-05-08T11:47:30.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":228073,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures II, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein."}],"balance_after":1277297,"source":{"system":"sec-edgar","filing":"0001104659-23-056865","document":"tm2314913-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923056865/tm2314913-1_4seq1.xml","form_type":"4"}},{"id":1901064,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2023-05-08T11:47:30.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":43761,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures II NY, LP"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein."}],"balance_after":245080,"source":{"system":"sec-edgar","filing":"0001104659-23-056865","document":"tm2314913-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923056865/tm2314913-1_4seq1.xml","form_type":"4"}},{"id":1901063,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, par value $0.0001 per share (\"Common Stock\")","published_at":"2023-05-08T11:47:30.000Z","date":"2023-04-12","kind":"exercise","planned":false,"acquired":true,"shares":758,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement ) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period (the \"Initial Milestone Event\") and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Initial Milestone Event occurred on April 12, 2023 and the Reporting Person's Pro Rata Portion of 4,000,000 shares of Common Stock were issued to the Reporting Person on April 19, 2023 in accordance with the Merger Agreement."}],"balance_after":4246,"source":{"system":"sec-edgar","filing":"0001104659-23-056865","document":"tm2314913-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923056865/tm2314913-1_4seq1.xml","form_type":"4"}},{"id":1901061,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Right to Receive Earnout Shares","published_at":"2023-05-08T11:47:13.000Z","date":"2023-01-26","kind":"grant","planned":false,"acquired":true,"shares":111566,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures Synecor, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein."}],"balance_after":111566,"derivative":{"underlying":"Common Stock","underlying_shares":111566},"source":{"system":"sec-edgar","filing":"0001104659-23-056864","document":"tm2314913-2_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923056864/tm2314913-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2023-01-30"}},{"id":1901060,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Right to Receive Earnout Shares","published_at":"2023-05-08T11:47:13.000Z","date":"2023-01-26","kind":"grant","planned":false,"acquired":true,"shares":456146,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures II, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."}],"balance_after":456146,"derivative":{"underlying":"Common Stock","underlying_shares":456146},"source":{"system":"sec-edgar","filing":"0001104659-23-056864","document":"tm2314913-2_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923056864/tm2314913-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2023-01-30"}},{"id":1901059,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Right to Receive Earnout Shares","published_at":"2023-05-08T11:47:13.000Z","date":"2023-01-26","kind":"grant","planned":false,"acquired":true,"shares":87522,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures II NY, LP"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."}],"balance_after":87522,"derivative":{"underlying":"Common Stock","underlying_shares":87522},"source":{"system":"sec-edgar","filing":"0001104659-23-056864","document":"tm2314913-2_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923056864/tm2314913-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2023-01-30"}},{"id":1901058,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Right to Receive Earnout Shares","published_at":"2023-05-08T11:47:13.000Z","date":"2023-01-26","kind":"grant","planned":false,"acquired":true,"shares":1516,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 4, 2022 (and as subsequently amended) by and among the Issuer and certain other parties named therein (the \"Merger Agreement\"), the Reporting Person has the contingent right to receive, for no additional consideration, the Reporting Person's Pro Rata Portion (as such term is defined in the Merger Agreement) of 8,000,000 shares of common stock of the Issuer (the \"Earnout Shares\") if, at any time from January 26, 2023 until January 26, 2028, the volume-weighted average price of the common stock of the Issuer is greater than or equal to (i) with respect to 4,000,000 Earnout Shares, $15.00 per share over any 20 trading days within any 30-trading day period and (ii) with respect to 4,000,000 Earnout Shares, $20.00 per share over any 20 trading days within any 30-trading day period."}],"balance_after":1516,"derivative":{"underlying":"Common Stock","underlying_shares":1516},"source":{"system":"sec-edgar","filing":"0001104659-23-056864","document":"tm2314913-2_4aseq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000110465923056864/tm2314913-2_4aseq1.xml","form_type":"4/A","original_submission_date":"2023-01-30"}},{"id":2042280,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-01-30T21:16:24.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":23250,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Received in connection with the Business Combination in exchange for options to acquire 50,000 shares of Orchestra common stock for $4.65 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F13","text":"The stock option vests in quarterly installments with a one year cliff beginning on August 18, 2023."}],"balance_after":23250,"derivative":{"exercise_price":10,"expiration_date":"2032-08-25","underlying":"Common Stock","underlying_shares":23250},"source":{"system":"sec-edgar","filing":"0000899243-23-002966","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000089924323002966/doc4.xml","form_type":"4"}},{"id":2042279,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-01-30T21:16:24.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":6975,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Received in connection with the Business Combination in exchange for options to acquire 15,000 shares of Orchestra common stock for $2.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The stock option is fully vested and exercisable."}],"balance_after":6975,"derivative":{"exercise_price":4.3011,"expiration_date":"2029-08-06","underlying":"Common Stock","underlying_shares":6975},"source":{"system":"sec-edgar","filing":"0000899243-23-002966","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000089924323002966/doc4.xml","form_type":"4"}},{"id":2042278,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-01-30T21:16:24.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":18600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Received in connection with the Business Combination in exchange for options to acquire 40,000 shares of Orchestra common stock for $2.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The stock option is fully vested and exercisable."}],"balance_after":18600,"derivative":{"exercise_price":4.3011,"expiration_date":"2028-08-07","underlying":"Common Stock","underlying_shares":18600},"source":{"system":"sec-edgar","filing":"0000899243-23-002966","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000089924323002966/doc4.xml","form_type":"4"}},{"id":2042277,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2023-01-30T21:16:24.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":519,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures Synecor, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Received in connection with the Business Combination in exchange for warrants to acquire 1,117 shares of Orchestra common stock for $10.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrants are immediately exercisable in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein."}],"balance_after":519,"derivative":{"exercise_price":21.5054,"expiration_date":"2023-05-31","underlying":"Common Stock","underlying_shares":519},"source":{"system":"sec-edgar","filing":"0000899243-23-002966","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000089924323002966/doc4.xml","form_type":"4"}},{"id":2042276,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2023-01-30T21:16:24.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":136097,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Received in connection with the Business Combination in exchange for warrants to acquire 292,682 shares of Orchestra common stock for $10.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrants are immediately exercisable in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein."}],"balance_after":136097,"derivative":{"exercise_price":21.5054,"expiration_date":"2023-05-31","underlying":"Common Stock","underlying_shares":136097},"source":{"system":"sec-edgar","filing":"0000899243-23-002966","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000089924323002966/doc4.xml","form_type":"4"}},{"id":2042275,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2023-01-30T21:16:24.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":43940,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures II NY, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Received in connection with the Business Combination in exchange for warrants to acquire 94,494 shares of Orchestra common stock for $10.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The warrants are immediately exercisable in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein."}],"balance_after":43940,"derivative":{"exercise_price":21.5054,"expiration_date":"2023-05-31","underlying":"Common Stock","underlying_shares":43940},"source":{"system":"sec-edgar","filing":"0000899243-23-002966","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000089924323002966/doc4.xml","form_type":"4"}},{"id":2042274,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-30T21:16:24.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":256623,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures Synecor, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for shares of Orchestra common stock that automatically converted into shares of New Orchestra common stock on a 1 for 0.465 basis upon the closing date of the Business Combination."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein."}],"balance_after":256623,"source":{"system":"sec-edgar","filing":"0000899243-23-002966","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000089924323002966/doc4.xml","form_type":"4"}},{"id":2042273,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-30T21:16:24.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":1049224,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures II, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for shares of Orchestra common stock that automatically converted into shares of New Orchestra common stock on a 1 for 0.465 basis upon the closing date of the Business Combination."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein."}],"balance_after":1049224,"source":{"system":"sec-edgar","filing":"0000899243-23-002966","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000089924323002966/doc4.xml","form_type":"4"}},{"id":2042272,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-30T21:16:24.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":201319,"ownership":{"direct":false,"nature":"By Ascent Biomedical Ventures II NY, LP"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Received in exchange for shares of Orchestra common stock that automatically converted into shares of New Orchestra common stock on a 1 for 0.465 basis upon the closing date of the Business Combination."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The Reporting Person is a managing member of ABV, LLC, which serves as general partner to Ascent Biomedical Ventures II NY, LP, Ascent Biomedical Ventures II, LP and Ascent Biomedical Ventures Synecor, LP. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest, if any, therein."}],"balance_after":201319,"source":{"system":"sec-edgar","filing":"0000899243-23-002966","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000089924323002966/doc4.xml","form_type":"4"}},{"id":2042271,"issuer":{"id":434,"kind":"organization","name":"Orchestra BioMed Holdings, Inc.","symbol":"OBIO"},"owners":[{"id":111191,"kind":"person","name":"Smith Geoffrey Wade","position":1,"cik":"0001418239","reported_name":"Smith Geoffrey Wade","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-01-30T21:16:24.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":3488,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock awards (\"RSAs\") that vest in two equal annual installments beginning on April 12, 2023, subject to the reporting person's continued service with Orchestra BioMed Holdings, Inc. (\"New Orchestra\") on such vesting date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in connection with the business combination of Orchestra BioMed, Inc. (\"Orchestra\") with Health Sciences Acquisitions Corporation 2 (the \"Business Combination\") in exchange for 1,621 RSAs of Orchestra."}],"balance_after":3488,"source":{"system":"sec-edgar","filing":"0000899243-23-002966","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814114/000089924323002966/doc4.xml","form_type":"4"}}]}